

Case report

Pseudohyperphosphatemia in a Patient with Multiple Myeloma

Yonggu Lee, M.D.¹, Taiyon Koo, M.D.¹, Joo-Hark Yi, M.D.¹, Jung-Hye Choi, M.D.¹
Sang-Woong Han, M.D.¹, Ille-Kyu Park, M.D.² and Ho-Jung Kim, M.D.¹

Departments of ¹Internal Medicine and ²Laboratory Medicine
Hanyang University Guri Hospital, Guri, Korea

Hyperphosphatemia is an unusual manifestation in patients with multiple myeloma without a significantly reduced glomerular filtration rate. Serum phosphate may be falsely elevated when a large amount of paraproteins is present in the serum, because ultraviolet light absorbance is elevated with the phosphomolybdate ultraviolet assay, which is most commonly used for serum phosphate measurement. This pseudohyperphosphatemia can be confirmed by deproteinization of the serum of patients. We report a case of multiple myeloma presenting with spurious hyperphosphatemia revealing pseudohyperphosphatemia by deproteinization of serum using sulfosalicylic acid.

Key Words : Paraproteinemia, Multiple myeloma, Pseudohyperphosphatemia

Introduction

Hyperphosphatemia is a common biochemical alteration in patients with renal failure, hypoparathyroidism, pseudohypoparathyroidism, metabolic acidosis, acromegaly, and tumor lysis syndrome¹⁾. Serum phosphate is elevated occasionally in patients with multiple myeloma. However, hyperphosphatemia is rare in patients with multiple myeloma unless renal failure is present, and most cases of multiple myeloma that present with hyperphosphatemia are accompanied by significant reduction of renal function below 30 mL/min of glomerular filtration rate (GFR)^{2, 3)}. We report a case of pseudohyperphosphatemia from a patient with multiple myeloma whose serum phosphate was constantly elevated without any symptom or sign of hyperphosphatemia.

Case Report

A 69-year-old woman suffered from dyspnea on exertion for a week. Severe anemia (hemoglobin 5.8 g/dL) and aortic stenosis was revealed on her blood test and echocardiogram. She was admitted for evaluation of anemia. The albumin-globulin ratio was reversed on her blood chemistry test, and Bence-Jones proteinuria was detected by routine urinalysis. The bone marrow biopsy and serum and urine protein electrophoreses were performed, and she was diagnosed as the immunoglobulin G (IgG) kappa type of multiple myeloma. The sequential investigation showed that the stage of multiple myeloma was IIIA. There were no skin lesions such as calcified nodules or eczema, and deep tendon reflexes were normal at both upper and lower extremities. Neither lytic bone lesion nor soft tissue calcification was found on her simple radiograms. Serum creatinine was 1.6 mg/dL, and estimated GFR calculated by the abbreviated Modification of Diet in Renal Disease (MDRD) study equation⁴⁾ was 29.7 mL/min/1.73 m². Serum calcium was

Received October 15, 2007. Accepted October 25, 2007.

Corresponding author: Sang-Woong Han, M.D.

Department of Internal Medicine, Hanyang University Guri Hospital, 249-1 Gyomoon-dong, Guri, 471-701, Korea

Tel: +82-31-560-2231, Fax: +82-31-551-2239

E-mail: cardion@hanyang.ac.kr

Table 1. Biochemical Data of the Patient with Multiple Myeloma and Spurious Hyperphosphatemia

Variables	Initial Presentation	Admission for 3 rd Chemotherapy
Total protein (g/dL)	11.3	9.9
Serum albumin (g/dL)	2.4	3.3
Serum phosphate (mg/dL)	12.7	13.1
Serum calcium (mg/dL)	8.3	7.9
Blood urea nitrogen (mg/dL)	24	30
Serum creatinine (mg/dL)	1.6	1.2
Serum uric acid (mg/dL)	10.3	6.5
Creatinine clearance (mL/min)	31.3	39.0
Estimated GFR (mL/min/1.73 m ²)	29.7	40.9
IgG (mg/dL)	9,810	6,250
IgA (mg/dL)	15	—
IgM (mg/dL)	24	—
i-PTH (pg/mL)	58.66	—
1,25(OH) ₂ vitamin D ₃ (pg/mL)	20.6	—
Urine calcium (mg/24h)	—	77.17
Urine phosphate (mg/24h)	—	85.41
TSH (μU/mL)	1.66	—

GFR, glomerular filtration rate; Estimated GFR was calculated by the abbreviated Modification of Diet in Renal Disease study equation; iPTH, intact parathyroid hormone; TSH, thyroid-stimulating hormone.

8.3 mg/dL, and intact parathyroid hormone was 55.9 pg/mL. However, serum phosphate was elevated to 12.7 mg/dL. She was given mephalan 8 mg/m² per day, prednisolone 60 mg/m² per day for 7 days every month, and oral CaCO₃ 500 mg three times a day in the middle of her meal. After three months when she was admitted for her 3rd cycle of chemotherapy, serum phosphate was still elevated to 13.1 mg/dL. Serum creatinine was 1.2 mg/dL, and estimated GFR was improved to 40.9 mL/min/1.73 m². Urinary phosphate collected for 24 hours was normal. Other laboratory findings at the initial presentation and admission for the 3rd cycle of chemotherapy are shown in Table 1.

The hyperphosphatemia was suspected to be spurious because intact parathyroid hormone was normal and estimated GFR was not remarkably decreased. Therefore, we took a single blood sample from her, and split it into two. One of the samples was treated with 20% sulfosalicylate to remove the paraprotein, and the serum phosphate, calcium, and albumin concentrations were compared between the two samples. The phosphate level was decreased to 3.5 mg/dL in the deproteinized sample, but it was 10.5 mg/dL in the other (Table 2).

Table 2. Serum Concentrations of Calcium, Phosphate, and Protein in the Patient before and after Deproteinization with Sulfosalicylic Acid

Variables	Before Deproteinization	After Deproteinization
Total protein (g/dL)	9.3	0.4
Serum albumin (g/dL)	3.0	—
Serum phosphate (mg/dL)	10.5	3.5
Serum calcium (mg/dL)	7.8	9.0

We analyzed the relationship between serum phosphate and serum globulin of the patient. Thirteen measurements were selected among all of the 21 simultaneous measurements of serum phosphate, calcium, total protein, and albumin, where the corrected calcium [= serum calcium + 0.8(4 – serum albumin)] was normal (8.2–10.5 mg/dL). Serum globulin was defined as the difference between serum protein and serum albumin. Spearman's correlation of SPSS 13.0 was used for statistic analysis. The concentration of serum phosphate was correlated positively with that of serum globulin ($r=0.637$, $p=0.035$, Fig. 1).

Finally, she was diagnosed as pseudohyperphosphatemia occurring due to the interference of serum paraprotein with phosphate measurement, and she stopped




Fig. 1. Relationship between serum globulin and phosphate in the multiple myeloma patient with pseudohyperphosphatemia.

her CaCO_3 medication.

Discussion

Pseudohyperphosphatemia is characterized by falsely elevated serum phosphate due to serum paraprotein in multiple myeloma patients without impairment of renal function and clinical manifestations of hyperphosphatemia. Phosphomolybdate ultraviolet (UV) assay is most commonly used for measurement of serum phosphate⁵⁾. It relies on the formation of a UV-absorbing complex between phosphate and molybdate. An inorganic phosphate reacts with an ammonium molybdate in the presence of sulphuric acid to form an ammonium phosphomolybdate complex, of which absorbance is measured at 340 nm³⁾. Serum of a patient with multiple myeloma has falsely elevated absorbance because paraproteins react with ammonium molybdate to make the serum cloudy⁵⁻⁸⁾. The level of serum phosphate returns to normal when it is measured after deproteinization with sulfosalicylate^{5-7, 9)}.

We searched the PubMed and Korean medical literature database (KMedbase and KoreaMed) for similar case reports. Keyword search under “pseudohyperphosphatemia” and “multiple myeloma” was performed. Eight case reports from PubMed and 2 case reports from Korean databases were found^{1, 5-12)} (Table 3).

Han et al. reported that pseudohyperphosphatemia was identified in 6 of 67 (9%) patients with multiple myeloma⁸⁾. Clinical characteristics of these cases are summarized in Table 3. Most cases were of the IgG type myeloma, stage IIIA, but other types and stages have been also reported. Existence of osteolytic lesion and serum calcium levels were inconsistent, but parathyroid hormone levels were all normal when measured. Serum creatinine levels was various, but there were no cases in which estimated GFR from the abbreviated MDRD study equation was below 30 mL/min/1.73 m².

The positive correlation between serum phosphate and globulin (or immunoglobulin) has been reported in several case reports of pseudohyperphosphatemia as in ours^{2, 3, 5-8)}. It suggests that the absorbance of UV light at 340 nm increases in parallel with the concentration of immunoglobulin¹³⁾. We think that the larger the tumor burden of multiple myeloma is, the greater the chances for pseudohyperphosphatemia to occur are. This could explain why the most pseudohyperphosphatemia cases were of IgG type and stage IIIA.

Interestingly, Mandry et al. reported a case of hyperphosphatemia due to phosphate-binding immunoglobulin from a patient with multiple myeloma¹⁾. The increased serum phosphate bound with immunoglobulin in the patient was demonstrated by comparison with serum phosphate in a normal control using a radioisotope method with ³²P. In this case, differentiation from the pseudohyperphosphatemia was possible because hyperphosphatemia still existed when the serum was treated with sulfosalicylate because of weak phosphate binding capacity of immunoglobulin not enough to precipitate with phosphate¹¹⁾. Pseudohyperphosphatemia does not have any necessity of treatment. In contrast to the cases of pseudohyperphosphatemia, this case of phosphate-binding immunoglobulin had a decreased level of 1,25(OH)₂ vitamin D₃, suggesting a role in induction of bone diseases such as osteomalacia.

In conclusion, pseudohyperphosphatemia should be considered when serum phosphate increases in a

Table 3. Case Reports of Pseudohyperphosphatemia in Patients with Multiple Myeloma

Case Reports	No.	Type of para-protein	Lytic Bone lesion	eGFR (mL/min/1.73m ²)	Phosphate (mg/dL)	Ca (mg/dL)	iPTH (pg/mL)	Para-protein (g/dL)	Stage	MX
Mandry et al. ¹⁾	1	IgGκ	Yes	Ccr=38 mL/min	11.1	8.68	20 (8–24)	6.5	NA	Phosphate binding IgG
Kim et al. ⁵⁾	1	IgGλ	No	46	7.6	8.6	NA	9.6	IIIA	PHP
Han et al. ⁸⁾	6	IgGκ	No	51	13.1	NA	NA	5.0	IIIA	PHP
		IgGκ	Yes	54	13.9	NA	NA	8.7	IIIA	PHP
		IgA	No	68	6.4	NA	NA	3.0	IIIA	PHP
		NA	Yes	45	15.7	NA	NA	4.1	IIIA	PHP
		IgG	Yes	49	16.0	NA	NA	7.5	IIIA	PHP
		IgG	No	60	6.4	NA	NA	4.6	IIIA	PHP
Barutcuoglu et al. ⁶⁾	1	IgGκ	Yes	39	30.5	12.5	NA	10.4	IIIA	PHP
Sonnenblick et al. ⁷⁾	3	IgGλ	Yes	68	29	9.8	NA	NA	IIIA	PHP
		IgGκ	Yes	NA	24	8.5	NA	NA	NA	PHP
		IgGκ	No	60	13	9.1	11.3	NA	NA	PHP
Stratta et al. ³⁾	1	IgGκ	No	79	7.4	9.6	(5–39)	2.7	NA	PHP
Marcu et al. ⁹⁾	1	IgGκ	Yes	97	12.5	9.2	NA	5.6	IIA	PHP
Oren et al. ¹⁰⁾	3	IgGκ	No	63	16	10.6	NA	2.5	IA	PHP
			Yes	53	7.6	8.9	NA	2.7	IIIA	PHP
			Yes	57	9.9	9.8	NA	2.3	IIIA	PHP
McCloskey et al. ²⁾	1	IgGλ	No	69	7.1	9.1	NA	7.2	IIIA	PHP
Cheikhrouhou	1	IgGκ	Yes	86	10.8	9.5	NA	7.8	IIIA	PHP
Abdelmoula et al. ¹¹⁾							51 (20–76)			

No, number of case; Ccr, Creatinine clearance. Serum creatinine was not available in the paper; NA, variable that was not available in the paper; eGFR, estimated glomerular filtration rate calculated by the abbreviated Modification of Diet in Renal Disease study equation; MX, mechanism of hyperphosphatemia; PHP, pseudohyperphosphatemia; iPTH, intact parathyroid hormone; Ca, serum calcium; IgGκ, immunoglobulin G kappa; IgGλ, immunoglobulin G lambda; IgA, immunoglobulin A.

patient with multiple myeloma whose renal function is not remarkably decreased. Analysis of the relationship between serum globulin and serum phosphate, and measurement of 1,25(OH)₂ vitamin D₃ and parathyroid hormone may be helpful for the identification and differentiation of hyperphosphatemia. When pseudohyperphosphatemia is suspected, measurement of serum phosphate after deproteinization with sulfosalicylate will prevent unnecessary phosphate-lowering treatments.

References

- 1) Mandry JM, Posner MR, Tucci JR, Eil C: Hyperphosphatemia in multiple myeloma due to a phosphate-binding immunoglobulin. *Cancer* **68**:1092–1094, 1991
- 2) McCloskey EV, Galloway J, Morgan MA, Kanis JA: Pseudohyperphosphatemia in multiple myeloma. *BMJ* **299**:1381–1382, 1989
- 3) Stratta P, Canavese C, Quaglia M, Lazzarich E, Morellini V, Brustia M, Bardone B, Bellomo G: A patient with unexplained hyperphosphatemia. *Nephrol Dial Transplant* **21**:2664–2666, 2006
- 4) Levey AS, Greene T, Kusek JW, Beck GJ, MDRD Study Group: A simplified equation to predict GFR from serum creatinine. [Abstract] *J Am Soc Nephrol* **11**:155, 2000
- 5) Kim KS, Kim DU, Lee WS, Chung WS: Pseudohyperphosphatemia in multiple myeloma. *Korean J Hematol* **29**:351–355, 1994
- 6) Barutcuoglu B, Parildar Z, Mutaf I, Habif S, Bayindir O: Spuriously elevated inorganic phosphate level in a multiple myeloma patient. *Clin Lab Haematol* **25**:271–274, 2003
- 7) Sonnenblick M, Eylath U, Brisk R, Eldad C, Hershko C: Paraprotein interference with colorimetry of phosphate in Serum of some patients with multiple myeloma. *Clin Chem* **32**:1537–1539, 1986
- 8) Han JY, Lee JH, Choi BG, Moon YS, Jin SW, Han WH, Kim YG, Hong YS, Kim HK, Kim BK, Lee KS, Kim DJ:

- Clinical Spectrums of Pseudohyperphosphatemia in Multiple Myeloma. *Korean J Med* **51**: 157–159, 1996
- 9) Marcu CB, Hotchkiss M: Pseudohyperphosphatemia in a patient with multiple myeloma. *Conn Med* **68**: 71–72, 2004
- 10) Oren S, Feldman A, Turkot S, Lugassy G: Hyperphosphatemia in multiple myeloma. *Ann Hematol* **69**: 41–43, 1994
- 11) Cheikhrouhou Abdelmoula L, Amira C, Chaabouni L, Kchir MM, Zouari R: Hyperphosphatemia in multiple myeloma. *Joint Bone Spine* **70**:541–542, 2003
- 12) Adler SG, Laidlaw SA, Lubran MM, Kopple JD: Hyperglobulinemia may spuriously elevate measured serum inorganic phosphate levels. *Am J Kidney Dis* **11**:260–263, 1988
- 13) Teppo AM: Immunoturbidimetry of albumin and immunoglobulin G in urine. *Clin Chem* **28**:1359–1361, 1982